Feb 14, 2022 8:30am EST Veru Reports that Independent Data Monitoring Committee for the Phase 3 Sabizabulin COVID-19 Clinical Study Recommends Continuing Study as Planned
Feb 09, 2022 6:30am EST Veru Reports First Quarter Fiscal 2022 Results as US FC2 Prescription Net Revenues Climb 27%
Feb 01, 2022 8:30am EST Veru Enters into Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company to Evaluate Enobosarm in Combination with Verzenio® in Phase 3 ENABLAR-2 Trial
Jan 31, 2022 8:30am EST Veru Announces FDA Grant of Fast Track Designation for Sabizabulin for the Treatment of Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome
Jan 26, 2022 8:30am EST Veru to Report Fiscal 2022 First-Quarter Financial Results, Host Conference Call on February 9th
Jan 10, 2022 8:30am EST Veru Announces FDA Grant of Fast Track Designation for Enobosarm for the Treatment of AR+ ER+ HER2- Metastatic Breast Cancer
Jan 03, 2022 8:30am EST Veru to Present Corporate Update at the H.C. Wainwright BioConnect Conference on January 10-13, 2022
Dec 13, 2021 8:30am EST Veru Announces FDA Approval of ENTADFI, a New Treatment for Benign Prostatic Hyperplasia
Dec 08, 2021 8:00am EST Veru Announces Presentation of Preclinical Evidence Supporting the Therapeutic Benefit of Enobosarm Alone or in Synergistic Combination with a CDK4/6 Inhibitor Against Palbociclib Resistant Metastatic Breast Cancer at the 2021 San Antonio Breast Cancer Symposium
